Finally An Osteoporosis Prescription That Will Help Inhibit Bone Loss
Amgen NASDAQ: AMGN pharmaceutical powerhouse just released a report stating outstanding performance results for Pivotal Postmenopausal Osteoporosis Trial for denosumab.
Study reached primary endpoint of Diminishing new vertebral fractures and secondary endpoints of reducing time to first non-vertebral and hip fractures; adverse events similar to placebo. The immediate past president of the National Osteoporosis Foundation Stated, ” I am particularly excited about these findings because they indicate that denosumab may offer an important new option for patients.”
Denosumab is the premier fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand, an important regulator of osteoclasts (these are the cells that break the bone down). Denosumab is being considered for its potential to inhibit all stages of osteoclast activity through a targeted mechanism. Denosumab is being studied for a variety of bone loss illnesses including postmenopausal osteoporosis, rheumatoid arthritis, and cancer treatment-induced bone loss in breast cancer and prostate cancer patients| in prostate cancer and breast cancer patients as well as for its potential to delay bone metastases and stop and treat bone destruction across many stages of cancer.
Often referred to as the “silent epidemic”, osteoporosis is a world wide problem illness, which is increasing in dominance as the world population both ages and increases. The World Health Organization (WHO) has just identified osteoporosis as a priority health issue in addition to other major non-communicable diseases. We are dependent on the pharmaceutical companies to help combat this horrendous disease.
According to Amgen the economic burden of osteoporosis is compared to as the “silent epidemi’ to that of other major chronic diseases; for example, in the U.S. the costs associated with osteoporosis-related fractures are equivalent to those of cardiovascular disease and asthma (i)(ii)(iii). It has been reported that osteoporosis results in more hospital bed-days than stroke, myocardial infarction or breast cancer (iv).
Pharmacist-clinical have been developing prescriptions drugs to help patient who experience serious side effects. These products are developed simultaneously the medications that aid in the treatment of the primary illness. The fact that information is available to help anticipate the possible effects and interactions drugs have with each other is awesome.
There are several drugs that both, prevent and treat osteoporosis. Some medicines increase bone thickness or slow the rate of bone loss. Even small amounts of new bone growth may diminish the risk of breaking bones. It is essential that you take vitamin D and calcium, exercise and eat well when you take osteoporosis prescriptions.
- CF Thompson
